C Max Schmidt
Overview
Explore the profile of C Max Schmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
229
Citations
8412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qadir M, Baril J, Yip-Schneider M, Schonlau D, Tran T, Schmidt C, et al.
medRxiv
. 2025 Jan;
PMID: 39830259
Background: Based on the Fukuoka and Kyoto international consensus guidelines, the current clinical management of intraductal papillary mucinous neoplasm (IPMN) largely depends on imaging features. While these criteria are highly...
2.
Fahrmann J, Yip-Schneider M, Vykoukal J, Spencer R, Dennison J, Do K, et al.
Cancer Lett
. 2025 Jan;
612:217450.
PMID: 39793753
In the current study, we assessed whether repeated measurements of a panel of protein biomarkers with relevance to pancreatic ductal adenocarcinoma (PDAC) improves lead time performance for earlier detection over...
3.
Leon-Letelier R, Chen Y, Ballaro R, Irajizad E, Do K, Maitra A, et al.
J Cancer Immunol (Wilmington)
. 2024 Dec;
6(4):148-153.
PMID: 39713022
No abstract available.
4.
Baril J, Ruedinger B, Nguyen T, Bilimoria K, Ceppa E, Maatman T, et al.
Surgery
. 2024 Oct;
179:108796.
PMID: 39358121
Background: Patients with clinical T2N0 (cT2N0) gastric adenocarcinoma are recommended to undergo either perioperative chemotherapy or upfront resection. If T2N0 disease is pathologically confirmed, patients may be observed without chemotherapy....
5.
Habib J, Kinny-Koster B, Javed A, Zelga P, Saadat L, Kim R, et al.
J Clin Oncol
. 2024 Sep;
42(36):4317-4326.
PMID: 39255450
Purpose: The benefit of adjuvant therapy for intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) remains unclear because of severely limited evidence. Although biologically distinct entities, adjuvant therapy practices...
6.
Kim R, Perri G, Rocha Castellanos D, Jung H, Kirsch M, Sacks G, et al.
Ann Surg
. 2024 Sep;
PMID: 39225424
Background: Little is known about the prognostic significance of pancreatic duct (PD) dilation following pancreatoduodenectomy for intraductal papillary mucinous neoplasms (IPMN). Although PD dilation is typically the hallmark radiographic feature...
7.
Yip-Schneider M, Muraru R, Rao N, Kim R, Rempala-Kurucz J, Baril J, et al.
Cureus
. 2024 Jun;
16(5):e60240.
PMID: 38872680
Introduction: Pancreatic cancer remains one of the deadliest cancers in the United States. Some types of pancreatic cysts, which are being detected more frequently and often incidentally on imaging, have...
8.
Leon-Letelier R, Dou R, Vykoukal J, Yip-Schneider M, Maitra A, Irajizad E, et al.
Clin Chem
. 2024 Jan;
70(1):102-115.
PMID: 38175578
Background: Increasing evidence implicates microbiome involvement in the development and progression of pancreatic ductal adenocarcinoma (PDAC). Studies suggest that reflux of gut or oral microbiota can lead to colonization in...
9.
Walia S, Zaidi M, McGuire S, Milam C, Fogel E, Sherman S, et al.
J Gastrointest Surg
. 2023 Dec;
27(12):2885-2892.
PMID: 38062321
Background: Sphincter of Oddi dysfunction (SOD) is managed primarily by endoscopic sphincterotomy (ES); however, surgical transduodenal sphincteroplasty (TDS) is a treatment option for select patients. In our high-volume pancreatico-biliary practice,...
10.
Kim R, Schick S, Muraru R, Roch A, Nguyen T, Ceppa E, et al.
J Gastrointest Surg
. 2023 Nov;
27(12):2815-2822.
PMID: 37962717
Background: Weekend readmissions have been previously associated with increased mortality after pancreatic resection, but the effect of weekend discharge is less understood. In this study, we aim to determine the...